Tumor markers as targets for selective diagnostic and therapeutic procedures

Anticancer Research

Volumn 16, Issue 4 B, 1996, Pages 2187-2192

  Roselli, Mario ^a   Guadagni, Fiorella ^b   Buonomo, Oreste ^a   Belardi, Augusto ^a   Ferroni, Patrizia ^c   Diodati, Alessandra ^a   Anselmi, Daniela ^a   Cipriani, Cesidio ^d   Casciani, Carlo U ^a   Greiner, John ^e   Schlom, Jeffrey ^e  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d S EUGENIO HOSPITAL   (Italy)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biological response modifiers; Diagnosis; Human cancer; Monoclonal antibodies; Radionuclides; Treatment

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; IMMUNOASSAY; IMMUNOSCINTIGRAPHY; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; GLYCOPROTEINS; HUMANS; NEOPLASMS; RADIOIMMUNODETECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 9444269798     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Mach JP, Bucchegger F, Forni M et al: Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol Today 2: 239-249, 1981.
2. Moldofshy PJ, Powe J, Milhern CB Jr et al: Metastatic colon carcinoma detected with radiolabeled F(ab')2 monoclonal antibody fragments. Radiology 149: 549-555, 1983.
3. Moldofsky PJ, Sears HF, Mulhern CB Jr et al: Detection ot metastatic tumor in normal-sized retroperitoneal lymph nodes by monoclonal antibody imaging. N Engl J Med 311: 106-107, 1985.
4. Hnatowich D, Griffin TW, Kosciuczyk C et al: Pharmacokinetics of an indium-111 labeled monoclonal antibody in cancer patients. J Nucl Med 26: 849-858, 1985.
5. Chatal JF, Saccavini JC, Fumoleau P et al: Immunoscintigraphy of colon carcinoma. J Nucl Med 25: 307-314, 1984.
6. Colcher D, Esteban JM, Carrasquillo JA et al: Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesion of colorectal cancer patients. Cancer Res 47: 1185-1189, 1987.
7. Esteban JM, Colcher D, Sugarbaker P et al: Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer 39: 50-59, 1987.
8. Sickle-Santanello BJ, O'Dweyer PJ, Mojzisik C et al: Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Dis Colon Rectum 30: 761-764, 1987.
9. Renda A, Salvatore M, Sava M et al: Immunoscintigraphy in the follow-up of patients operated on for carcinoma of the sigmoid and rectum. Preliminary report with a new monoclonal antibody B72.3. Dis Colon Rectum 30: 683-686, 1987.
10. Sears HF, Mattis J, Herlyn D et al: Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1: 762-765, 1982.
11. Miller RA, Oserott AR, Stratte PT, and Levy R: Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62: 988-995, 1983.
12. Oldham R, Foon KA, Morgan AC et al: A monoclonal antibody therapy of malignant melanoma: In vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol 2: 1235-1244, 1984.
13. Pimm MV, Jones JA, Price MR, Middle JG, Embleton MJ and Baldwin RW: Tumour localization of monoclonal antibody against a rat mammary carcinoma and suppression of tumour growth with adriamycin-antibody conjugates. Cancer Immunol Immunother 12: 125-134, 1982.
14. Varki NM, Reisfeld RA and Walker LE: Effect of monoclonal antibody-drug conjugates on the in vivo growth of human tumors established in nude mice. In: Reisfeld RA, Sell S, eds. Monoclonal antibodies and cancer therapy: Proceedings of the Rochc-UCLA Symposium held in Park City. New York: Lis; 217-214, 1985.
15. Gilliland DG, Steplewski Z, Collier RJ, Mitchell KF, Chang TH and Koprowski H: Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cell. Proc Natl Acad Sci USA 77: 4539-4543, 1980.
16. Fitzgerald D, Waldmann T, Willingham M and Pastan I: Pseudomonas exotoxin-anti-TAC cell-specific immunotoxin active against cell expressing the human cell growth factor receptor. J Clin Inv 7: 966-971, 1984.
17. Epenetos AA, Courtenay-Luck N, Pickering D, et al: Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen. Br Med J 290: 1463-1466, 1985.
18. Esteban JM, Schlom J, Mornex F and Colcher D: Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: Histological and autoradiographic study of effects on tumors and normal organs. Eur J Cancer Clin Oncol 23: 643-655, 1987.
19. DeNardo SJ, DeNardo GL, O'Grady LF et al: Treatmant of B cell malignancies with 1311 LYM-I monoclonal antibodies. Int J Cancer Suppl 3: 96- 101, 1988.
20. Colcher D, Carrasquillo JA, Esteban JM et al: Radiolaheled monoclonal antibody B72.3 localization in metastatic lesion of colorectal cancer patients. Nucl Med Biol 14: 251-257, 1987.
21. Colcher D, Esteban J, Carrasquillo JA et al: Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 47: 4218-4224, 1987.
22. Schlom J, Colcher D, Roselli M et al: Tumor targeting with monoclonal antibody B72.3. Nucl Med Biol 16: 137-142, 1989.
23. Carrasquillo JA, Sugarbaker P, Colcher D et al: Radioimmunoscintigraphy of colon cancer with I-131-labeled B72.3 monoclonal antibody. J Nucl Med 29: 1022-1030, 1988.
24. Yokoyama K, Carrasquillo JA, Chang et al: Differences in biodistribution of indium-111 and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer. J Nucl Med 30: 320-327, 1989.
25. Martin EW Jr, Mojzisik CM, Hinkle GH et al: Radioimmunoguided surgery using monoclonal antibody. Am J Surg 156: 380-392, 1988.
26. Nieroda CA, Mojzisik C, Sardi A et al: Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3. Surg Gynecol Obstet 169: 35-41, 1989.
27. Choen AM, Martin EW, Lavery I et al: Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch Surg 126: 349-351, 1991.
28. Arnold MW, Schneebaum S, Berens A, Mojzisik C, Hinkle G and Martin EW, Jr: Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer. Surgery 112: 624-630, 1992.
29. Reynolds JC, Del Vecchio S, Sakahara H et al: Anti-murine response to mouse monoclonal antibodies: clinical findings and implications. Nucl Med Biol 16: 121-125, 1989.
30. Seccamani E, Tattanelli M, Mariani M, Sprenzi E. Scassellati GA and Siccardi AG: Nucl Med Biol 16: 167-170, 1989.
31. Colcher D, Milenic DE, Ferroni P et al: In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med 31: 1133-1142, 1990.
32. Schlom J, Milenic DE, Roselli M et al: New concepts in monoclonal antibody based radioimmunodiagnosis and radioimmunotherapy of carcinoma. Nucl Med Biol 18: 425-435, 1991.
33. Colcher D, Milenic DE, Roselli M, et al.: Characterization and biodistribution of recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res 49: 1738-1745, 1989.
34. Hutzell P, Kashmiri S, Colcher D et al: Generation and characterization of a recombinant/chimeric B72.3 (human Y1) Cancer Res 51: 181 -189, 1991.
35. Colcher D, Bird M, Roselli M et al: In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 82: 1191-1197, 1990.
36. Schlom J, Molinolo A, Simpson JF et al: Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 82: 763-771, 1990
37. Gansow OA, Brechbiel MW, Mirzadeh S, Colcher D, and Roselli M: Chelates and Antibodies: Current Methods and New Directions. In: Cancer Imaging with Radiolabeled Antibodies. Eds Goldenberg DM: Kluwer Academic Publ, pp. 153-171, 1990.
38. Roselli M, Schlom J, Gansow OA et al: Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies. Nucl Med Biol 18: 389-394, 1991.
39. 212Bi for α-particle mediated radioimmunotherapy. J Chem Soc Chem Commun 17: 1169-1170, 1991.
40. Gansow OA, Brechbiel MW, Pippin CG et al. Lead and Bismuth complexes of functionalized DTPA ligands and of the polyazacycloalkane-N-acetic acid DOTA. Utility for radioimmunoimaging and radioimmunotherapy. Antibody, Immunoconjugates, and Radiopharmaceuticals 4: 413425, 1991.
41. Roselli M, Schlom J, Gansow OA et al: Comparative biodistribution of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med 30: 672-682, 1989.
42. Prehn RT: Analysis of antigens heterogeneity within individual 3-methylcholantrene-induced mouse sarcomas. J Natl Cancer Inst 45: 1039-1044, 1970.
43. Miller FR and Heppner GH: Immunologie heterogeneity of tumor cell subpopulations from a single mouse mammary tumor. J Natl Cancer Inst 63: 1457-1461, 1979.
44. Horand Hand P, Nuti M, Colcher D, Schlom J: Definition of antigenic heterogeneity and modulation among mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens. Cancer Res 43: 728-735, 1983.
45. 2-microglobulin and HLA antigens on human Iymphoid cells by interferon. Proc Natl Acad Sci USA 75: 6215-6219, 1978.
46. Wallach D, Fellous M, Revel M: Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs. Nature 299: 833-836, 1982.
47. Oreiner JW, Horand-Hand P, Noguchi P, Fisher, PB, Pestka S and Schlom J: Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte α-interferon treatment. Cancer Res 44: 3208-3213, 1984.
48. Greiner JW, Guadagni F, Noguchi P et al: Recombinant interferon enhances monoclonal antibody targeting of carcinoma lesions in vivo. Science 235: 895-899 1987.
49. Guadagni F, Schlom J, Pothen S, Pestka S and Greiner JW: Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon. Cancer Immunol Immunother 26: 222-230. 1988.
50. Guadagni F, Schlom J, Johnston W et al: Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst 81: 502-512, 1 989.
51. Greiner JW, Dansky Ullmann C, Nieroda C et al: Improved immunotherapeutic efficacy of an anticarcinoma monoclonal antibody (CC49) when given in combination with IFN-y. Cancer Res 53: 600-608, 1993.
52. Greiner JW, Guadagni F, Goldestein D et al: Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cell. J Clin Oncol 10: 735-746, 1992.
53. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D: Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 46: 850-857, 1986.
54. Sheer DG, Schlom J and Cooper HL: Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. Cancer Res 48: 6811-6818, 1988.
55. Katari RS, Fernsten PD and Schlom J: Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas. Cancer Res 50: 4885-4890, 1990.
56. Muraro R, Kuroki D, Wunderlich D et al: Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor associated glycoprotein 72 antigen. Cancer Res 48: 4588-4596, 1988.
57. Colcher D, Minelli MF, Roselli M, Muraro R, Simpson-Milenic D and Schlom J: Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies, Cancer Res 48: 4597-4603, 1988.
58. Molinolo A, Simpson JF, Thor A, Schlom J: Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 50: 1291-1298, 1990.
59. 177Lutetium-labeled immunoconjugate. Cancer Res 51: 2889-2896, 1991.